IL17RB and ovarian cancer: A2780cis cells were significantly less sensitive to cisplatin treatment compared with parental A2780 cells (p = .0055, t [2.5] = −9.1, Welch's two‐sample t‐test); however, parental A2780 and A2780cis cells were equally sensitive to KH‐4‐43 treatment (p = .91, t [4] = .12, Welch's two‐sample t‐test) (Figure 3D), highlighting the potential of targeting CRL4 in platinum‐refractory ovarian cancer and supporting the potential utility in both the front line and refractory settings.